Both Teplizumab and Spiriva Respimat offer similar effectiveness, with differences in speed and duration of relief.

Both drugs have comparable safety profiles, with mild side effects that are generally well-tolerated.

Both drugs are low-risk for addiction when used properly, with minimal potential for misuse.

Spiriva Respimat offers various forms, including liquid and injectable options, providing more flexibility.

Both drugs have some contraindications depending on individual health conditions, but neither has major restrictions.

Both drugs are good options depending on the patient’s needs, with Teplizumab better for quick relief and Spiriva Respimat for long-term management.